Project Grant HT94252510414
Award Date
7/15/25
Completion Date
7/14/27
Dollars Obligated
$526K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The federal Project Grant award, ID HT94252411040, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $879,692 award, with a performance period from September 30, 2024 to September 29, 2027, supports the Fred Hutchinson Cancer Center's research on "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance." This innovative research project aims to develop novel...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
The federal Project Grant award with ID HT94252510091 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $1,927,373.00 grant, awarded on February 15, 2025, supports the development of targeted therapies for metastatic prostate cancers classified by subtypes of DNA repair deficiency at the Fred Hutchinson Cancer Center in Seattle, Washington. As a leading cancer research institution, the Fred Hutchinson Cancer Center conducts...
The U.S. Department of Defense's Defense Health Agency awarded a $526,042 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to support research aimed at identifying and targeting mechanisms of prostate cancer therapy resistance driven by the tumor microenvironment. The project will be conducted over a 2-year period from May 1, 2024 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). This research grant...
The Defense Health Agency awarded a $528,000 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to assess the landscape of cell surface targets in metastatic prostate cancer. This 2-year grant, which began on April 15, 2024, is funded through the Military Medical Research and Development program (CFDA 12.420). The project aims to advance biomedical research on innovative therapeutic approaches for cancer, in line with the program's goals of...
The Fred Hutchinson Cancer Center was awarded a $1.32 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year award will support prostate cancer research from July 1, 2022 to June 30, 2025. Through this funding, Fred Hutchinson Cancer Center will conduct basic, applied, and advanced biomedical research to develop new medical solutions for prostate cancer. The Military Medical Research and...
This federal Project Grant award of $1,460,695.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund the "DEVELOPMENT AND VALIDATION OF AN EPIGENOMIC LANDSCAPE AND NOVEL IMMUNOTHERAPY IN PROSTATE CANCER DISPARITIES" over the period of September 1, 2025 to August 31, 2028. The award recipient is The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc., a non-profit organization...
This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), provides $1,390,847.00 to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. to investigate the mechanistic role and therapeutic targeting of the cohesin RAD21 protein in metastatic prostate cancer. The award period runs from September 1, 2025 to August 31, 2028. The research aims to advance medical...
This $5,149,107 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides funding to the Fred Hutchinson Cancer Center (also known as the Seattle Cancer Care Alliance) for advanced biomedical research focused on defining human correlates of super-evasive disseminated tumor cells, their pathological relevance, and methods to eradicate them. The 4-year project, running from July 2025 to June 2029, will leverage the...